Search

Displaying results 91 - 100 of 2691 in total
  1. Drug

    Ferrous cation

    go.drugbank.com/drugs/DB14510
    Investigational

    Products: HAEMOPROCAN 50MG FTA, HAEMOPROCAN 100MG FTA
  2. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

    Synonyms: Revacept
  3. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for ...

    Products: MOXIFLOXACIN AL 400MG FTA, MOXIFLOXACIN HEU 400MG FTA
  4. Drug

    Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells

    go.drugbank.com/drugs/DB18654
    Investigational

    Synonyms: Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells, Autologous Chimeric Antigen Receptor (CAR) Modified Recombinant T Cells Targeting EGFRvIII
  5. Drug

    LB54640

    go.drugbank.com/drugs/DB18331
    Investigational

    LB54640 is orally-administered small molecule agonist of the melanocortin 4 receptor.

    Synonyms: Oral melanocortin 4 receptor agonist, Small molecule melanocortin 4 receptor agonist
  6. Drug

    Efavirenz

    go.drugbank.com/drugs/DB00625
    ApprovedInvestigational

    Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type ...

    Products: EFAVIRENZ HEXAL 600MG FTA
  7. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH). … It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.

    Synonyms: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER, (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-
  8. Drug

    Tadalafil

    go.drugbank.com/drugs/DB00820
    ApprovedInvestigational

    [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH.

    Products: TALMANCO 20MG FTA, TADALAFIL AOP 20MG FTA
  9. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology

    Categories: Interleukin-31 Receptor alpha AntagonistSynonyms: Immunoglobulin G2, anti-(interleukin 31 receptor A) (human-Mus musculus monoclonal CIM331 γ-chain), disulfide with human-Mus musculus monoclonal CIM331 κ-chain, dimer, immunoglobulin G2-kappa, anti-[Homo sapiens IL31RA (interleukin 31 receptor subunit alpha)], humanized monoclonal antibody gamma2 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-2*02 (83.70%) -(IGHD
  10. Indication

    Ovulatory Dysfunction

    go.drugbank.com/conditions/DBCOND0045186
    Drugs: Clomifene